Mohamad E. Allaf, MD

Mohamad E. Allaf, MD

Johns Hopkins Medicine

Baltimore, Maryland

Mohamad E. Allaf, MD, is Professor of Urology and Oncology, as well as Director of the Department of Urology and the Brady Urological Institute, Urologist-in-Chief of the Johns Hopkins Hospital, and Director of Minimally Invasive and Robotic Surgery. Dr. Allaf earned his medical degree from Johns Hopkins University, where he also completed his residency in urology.

Dr. Allaf is a world renowned surgeon-scientist who has performed more than 2,000 robotic procedures and published over 250 peer reviewed research papers in the field's best journals. Dr. Allaf has used Dr. Patrick Walsh's method of radical prostatectomy as the basis for his own anatomic method to this complex operation.

Dr. Allaf is also amongst the leaders in kidney cancer surgery, having served on the American Urological Association (AUA) Guideline Committee for Kidney Cancer. He led a team who performed the rigorous analysis to help inform the most recent guidelines that was funded by the Agency for Healthcare Research and Quality (AHRQ). He is best known for his ability to save the kidney and remove the tumor in patients with kidney tumors.

Dr. Allaf runs a research endeavor aiming to decrease the morbidity associated with the treatment of cancer, and he has mentored numerous leaders in academic urology. He is actively involved in fundraising for research and education, and believes in expanding the base of support in order to advance this important mission.

Talks by Mohamad E. Allaf, MD

Novel Imaging for Renal Mass Characterization

Novel Imaging for Renal Mass Characterization

Posted by | Oct 2024

In this 18-minute presentation, Mohammed E. Allaf, MD, discusses novel imaging techniques for renal mass characterization, emphasizing advancements and their clinical implications. He outlines the traditional imaging modalities such as ultrasound, CT, and MRI, which, despite their utility, have limitations that lead to indeterminate findings, necessitating further diagnostic procedures.

Dr. Allaf highlights multiparametric MRI (mpMRI), contrast-enhanced ultrasound (CEUS), and PET imaging as tools in this advanced era of molecular imaging. For example, advancements in PET imaging contribute significantly to the management of renal cell carcinoma, enabling more accurate staging and potentially guiding targeted therapies. He underscores that radiologists, urologists, and oncologists must collaborate to interpret imaging results accurately and develop individualized treatment plans for patients.

Read More
The Battle of Biopsies: Results of a Multi-institutional Randomized Trial of Transrectal vs Transperitoneal Prostate Biopsy

The Battle of Biopsies: Results of a Multi-institutional Randomized Trial of Transrectal vs Transperitoneal Prostate Biopsy

Posted by | Oct 2024

Mohammed E. Allaf, MD, delivers a compelling analysis of the outcomes from a multi-institutional randomized trial comparing transrectal and transperitoneal prostate biopsy techniques. This study, which Dr. Allaf presents in detail, addresses a critical question in urological practice: which biopsy method offers the best balance between diagnostic accuracy and patient safety?

Dr. Allaf begins this 21-minute conversation by discussing the historical preference for transrectal prostate biopsy. However, he highlights the growing concerns regarding infection rates and the potential for antibiotic resistance associated with this technique. In contrast, although less commonly used, the transperitoneal approach is posited to reduce the risk of infections and complications.

Read More
Management of Small Renal Tumors: A Guidelines Based Approach

Management of Small Renal Tumors: A Guidelines Based Approach

Posted by | Oct 2024

Mohammed E. Allaf, MD, presents a comprehensive overview of managing small renal tumors, focusing on a guidelines-based approach that integrates the latest evidence and expert consensus in the evolving landscape of renal tumor management.

In this 20-minute presentation, Dr. Allaf outlines the current guidelines for evaluating small renal masses. He highlights the critical factors influencing management choices, including gender, tumor size, location, patient comorbidities, age, and family history.

In discussing treatment options, Dr. Allaf examines active surveillance, radical or partial nephrectomy, and ablative therapies and the indications for each approach. He also touches on future directions in treatment and imaging while emphasizing the benefits of the current guidelines.

Read More
Role of Lymphadenectomy in the Surgical Treatment of Clinical Localized Prostate Cancer

Role of Lymphadenectomy in the Surgical Treatment of Clinical Localized Prostate Cancer

Posted by | Aug 2024

Mohamad E. Allaf, MD, discusses the use cases for lymphadenectomy in the surgical treatment of clinically localized prostate cancer. Dr. Allaf begins by addressing the rationale for performing lymphadenectomy, emphasizing its diagnostic and therapeutic potential in prostate cancer management.

A central focus of the presentation is the debate surrounding lymphadenectomy and its implications for patient outcomes. Dr. Allaf reviews the current evidence, highlighting studies that suggest extended lymphadenectomy may provide superior oncologic control by increasing the likelihood of detecting metastatic nodes in high- and intermediate-risk patients. Dr. Allaf also delves into the nuances of patient selection and determining when and how to integrate lymphadenectomy into the surgical treatment of prostate cancer.

Read More
  • 1
  • 2